Pat is a professor of Ophthalmology at Harvard Medical School and Associate Chief of Basic & Translational Research at Massachusetts Eye and Ear. She is a world-renowned ocular angiogenesis expert who has made significant contributions in the identification of vascular endothelial growth factor(VEGF) as a primary ocular angiogenesis driver, leading to the approval of anti-VEGF therapies for treating retinal diseases. She also developed the oxygen-induced retinopathy(OIR) mouse model, which is widely used for preclinical studies of anti-angiogenic ocular therapeutics. She has published more than 160 papers and is the recipient of the Alcon Research Institute Award, the Cogan Award from ARVO, the Rous-Whipple Award from the American Society of Investigative Pathology, the Endre A. Balazs Award from the International Society for Eye Research, and the Proctor Medal from ARVO

Carl is Chief and Director of the Retina Service, Wills Eye Hospital in Philadelphia. He is the Principle Investigator of several major international clinical trials investigating new forms of treatment for a variety of retinal conditions including AMD and DR/DME. He is the Founder of Wills Eye Clinical Retina Research Unit and the former chairman of the Will Eye Institutional Review Board and the American Academy’s Basic and Clinical Science Course (BCSC) Retina Section committee. He has authored over 100 scientific papers, lectured nationally and abroad, and has published five major textbooks in the field. He has run several instructional courses at the annual American Academy of Ophthalmology meeting and is a recipient of the Academy's Achievement and Senior Achievement Awards in addition to the Secretariat Award.

Peter is Chief of Ophthalmology at the Sunnybrook Health Centre and an Associate Professor in the Department of Ophthalmology at the University of Toronto. He is a retinal surgeon with extensive experience in clinical trials for anti-angiogenic agents and is in search for better treatments for wet age-related macular degeneration(AMD) and diabetic retinopathy(DR). He specializes in the diagnosis and treatment of diseases of the retina, macula, and vitreous. With a burgeoning interest in international ophthalmology and pediatric retinal diseases such as Retinopathy of Prematurity(ROP), Peter seeks for opportunities volunteering his expertise.

Sejoon is an Associate Professor of Ophthalmology at Seoul National University Bundang Hospital(SNUBH). He is an active scientific researcher and ophthalmology medical doctor specializing in Pharmacokinetics(PK) study which is increasingly important for the successful development of anti-angiogenic therapies. He is also involved in multiple global clinical trials of novel retinal treatments and biosimilar agents, and has recently led the phase 3 global clinical trials of Lucentis biosimilar developed by Samsung Bioepis. He has published more than 230 peer-reviewed papers.

Bob is a senior scientist at Sunnybrook Health Center located in Toronto and a professor at the University of Toronto. Neither an ophthalmologist nor an ocular specialist, he is a global scholar in the field of angiogenesis--a key pathologic mechanism of retinal diseases. His scientific interest mostly lies in improving clinical translation and overcoming anti-angiogenic drug resistance. He has published around 420 papers with a total of 45,000 cited cases.